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Background: In 2016/17, seasonal influenza vaccine 
was less effective in those aged 65 years and older 
in the United Kingdom. We describe the uptake, influ-
enza-associated mortality and adjusted vaccine effec-
tiveness (aVE) in this age group over influenza seasons 
2010/11–2016/17. Methods: Vaccine uptake in 2016/17 
and five previous seasons were measured using a 
sentinel general practitioners cohort in England; the 
test-negative case-control design was used to esti-
mate pooled aVE by subtype and age group against 
laboratory-confirmed influenza in primary care from 
2010–2017. Results: Vaccine uptake was 64% in 
65–69-year-olds, 74% in 70–74-year-olds and 80% in 
those aged 75 and older. Overall aVE was 32.5% (95% 
CI: 11.6 to 48.5); aVE by sub-type was 60.8% (95% CI: 
33.9 to 76.7) and 50.0% (95% CI: 21.6 to 68.1) against 
influenza A(H1N1)pdm09 and influenza B, respec-
tively, but only 5.6% (95% CI: -  39.2 to 35.9) against 
A(H3N2). Against all laboratory-confirmed influenza 
aVE was 45.2% (95% CI: 25.1 to 60.0) in 65–74 year 
olds; -  26.2% (95% CI: -  149.3 to 36.0) in 75–84 year 
olds and -  3.2% (95% CI: -  237.8 to 68.5) in those 
aged 85 years and older. Influenza-attributable mor-
tality was highest in seasons dominated by A(H3N2). 
Conclusions: Vaccine uptake with non-adjuvanted, 
normal-dose vaccines remained high, with evidence 
of effectiveness against influenza A(H1N1)pdm09 and 
B, though poor against A(H3N2), particularly in those 
aged 75 years and older. Forthcoming availability of 
newly licensed vaccines with wider use of antivirals 
can potentially further improve prevention and control 
of influenza in this group.
Introduction
The United Kingdom (UK), like many other countries 
in Europe, North America and Australasia, has a long-
standing inactivated influenza vaccine programme 
including for all those over 65 years of age. The UK uni-
versal influenza vaccine programme for those aged 65 
years and older was first started in 2000/01 [1], follow-
ing several seasons of intense A(H3N2) activity asso-
ciated with substantial morbidity and excess mortality 
particularly in this older age group [2]. This together 
with vaccination effectiveness (VE) estimates at that 
time [3] informed the decision to offer influenza vac-
cine free of charge to all individuals aged 65 years and 
older in addition to high-risk groups, such as those 
with underlying chronic respiratory and cardiovascular 
disease.
Following this change in vaccine policy, influenza vac-
cine uptake for those aged 65 years and older has 
increased, reaching a high point in excess of the World 
Health Organization (WHO) and European Council rec-
ommendation of 75% in 2005/06 in England. Although 
there has been a gradual decline in uptake since that 
time, coverage was still 70.5% in 2016/17, ranging from 
66.6% to 74.5% in other UK countries [4]. Although 
excess influenza-associated mortality has reduced 
since the high levels observed during the 1990s, there 
is still a substantial disease burden on the population, 
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particularly in those aged 65 years and older and most 
often during seasons with intense influenza A(H3N2) 
activity [5]. A recently published UK VE study for the 
2016/17 season, when influenza A(H3N2) was again the 
dominant circulating strain, found moderate to good VE 
in children and younger adults but no evidence of effec-
tiveness in those aged 65 years and older [6]. Newer 
vaccines that provide direct protection against influ-
enza e.g. adjuvanted, higher dose, cell-based or are 
recombinant [7] are becoming increasingly available. 
These, in combination with indirect protection from the 
progressive rollout of the UK childhood influenza vac-
cine programme, means that the potential role of these 
alternative interventions in reducing disease burden in 
this age group needs to be further explored [7].
The aim of this study was to further describe the recent 
uptake of influenza vaccine in those aged 65 years and 
older (including prior vaccine history) to measure influ-
enza-associated mortality in this age group and to esti-
mate the effectiveness of influenza vaccine over the 
period 2010–2017. The results will help inform optimal 
approaches to further mitigate the impact of influenza 
in this enlarging group.
Methods
Influenza vaccine uptake in those aged 65 years 
and older, influenza season 2016/17
The previously described Royal College of General 
Practitioners (RCGP) Research Surveillance Centre 
(RSC) VE cohort was used to measure vaccine uptake 
and obtain prior vaccine history [8]. The RCGP RSC 
cohort is composed of the entire registered population 
in participating RSC sentinel practices across England. 
The entry date to the cohort was 1 September 2016 and 
exit date was 31 May 2017, with influenza vaccination 
history for the five previous seasons. The cohort was 
restricted to patients that were alive, aged 65–100 
years of age and registered for at least 1 year with any 
of the practices during the study period.
Influenza-associated mortality in those 
aged 65 years and older, influenza seasons 
2011/12–2016/17
Using the weekly number of all-cause death registra-
tions for those aged 65 years and older in England, 
available from the Office for National Statistics (ONS) 
for the period September 2011–September 2017, a pre-
viously described multiplicative Poisson regression 
model (the FluMoMo model) was used to estimate 
the number of deaths associated with influenza [9]. In 
brief, the model baseline adjusts for seasonal and tem-
poral variation by including a sine curve and trend. In 
addition, the model simultaneously controls for influ-
enza activity (IA) and extreme temperature (ET). As the 
impact of influenza may vary by season, IA is included 
separately from each influenza season and calculated 
as weekly influenza-like illness (ILI) consultation rate 
multiplied by the swab positivity rate. While the effect 
of influenza is allowed to vary each season, the effect 
of extreme temperature is assumed constant over time, 
and is included in the model as two variables; a sum-
mer effect (s) and a winter effect (w), both defined as 




























*seasonality(t) comprise the 
baseline, and the remainder impacts of IA and ET.
The FluMoMo model was run separately for each age 
group (65–74 years and those aged 75 years and older) 
and by sub-type, (influenza A and B).
Vaccine effectiveness in those aged 65 years and 
older, influenza seasons 2010/11–2016/17
Data sources and study population
The Test Negative Case (TNCC) control design has been 
used to measure vaccine effectiveness against labo-
ratory-confirmed influenza infection that has resulted 
Table 1
Influenza vaccine uptake and prior vaccine history by age group, Royal College of General Practitioners (RCGP RSC) 
participating practices, England, influenza seasons 2010/11–2016/17 (n = 283,188)

















Unvacc Vacc Unvacc Vacc Unvacc Vacc Unvacc Vacc Unvacc Vacc
0 23,403 5,467 11,457 1,482 10,956 1,673 3,694 655 49,510 9,277
1 3,915 6,868 2,145 1,556 1,886 1,531 678 713 8,624 10,668
2 1,831 7,683 1,469 2,733 1,373 2,672 555 1,183 5,228 14,271
3 1,178 8,115 1,144 3,972 1,090 3,551 469 1,538 3,881 17,176
4 820 8,925 1,088 6,564 1,181 6,788 571 2,873 3,660 25,150
5 601 18,759 1,122 36,566 1,670 54,857 987 21,181 4,380 131,363
All 31,748 55,817 18,425 52,873 18,156 71,072 6,954 28,143 75,283 207,905
Unvacc: unvaccinated; Vacc: vaccinated.
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in acute influenza-like illness consultation in primary 
care. Five sentinel primary care surveillance schemes 
across the UK provided swabbing data (two from 
England, one each from Northern Ireland, Scotland and 
Wales). Details of these swabbing schemes have been 
published previously [10]. The study period was from 
1 October 2010 until 19 March 2017: a period when 
non-adjuvanted, non-high dose inactivated influenza 
vaccine (IIV) was administered to those aged 65 years 
and older through primary care in the UK. Cases were 
defined as people aged 65 years and older consulting 
their general practitioner (GP) with an acute ILI who 
were swabbed and tested positive for influenza A or 
B with real-time polymerase chain reaction (RT-PCR). 
Controls were people aged 65 years and older with 
ILI who tested negative for influenza A and B. ILI was 
defined as an acute respiratory illness with physician-
diagnosed fever or history of fever in the previous 7 
days. Patients were swabbed as part of clinical care 
with verbal consent. A standardised questionnaire was 
completed by the patient’s GP at the time of swabbing 
collecting key demographic, clinical and epidemiologi-
cal information including date of birth, date of onset of 
illness, date of the swab, date of vaccination that sea-
son, sex and underlying clinical risk group as per the 
Green Book (national immunisation) guidance [11].
Laboratory confirmation was undertaken using RT-PCR 
assays for circulating influenza A, influenza B and other 
respiratory viruses at the national laboratory [12,13]. 
Samples in England were sent to the Public Health 
Agency England (PHE) Reference Virus Unit, Colindale 
(RCGP RSC scheme) or one of the specialist regional 
microbiology laboratories (SMN scheme). Samples in 
Wales were sent to the Public Health Wales Specialist 
Virology Centre, Cardiff and samples in Scotland were 
sent to the West of Scotland Specialist Virology Centre, 
Table 2
Average annual influenza-associated mortality rates by age groups and influenza type over five seasons, England, influenza 
seasons 2011/12–2016/17














2011/12 368 8.0 428 9.3
A(H3N2)/B (303 to 438) (7.0 to 9.5) (344 to 519) (7.5 to 11.3)
2012/13 590 12.2 13 0.3
A(H3N2)/B (500 to 684) (10.3 to 14.1) (0 to 45) (0.0 to 0.9)
2013/14 16 0.3 22 0.4
A(H1N1)pdm09 (0–48) (0.0 to 1.0) (3 to 50) (0.1 to 1.0)
2014/15 2,378 46.1 143 2.8
A(H3N2)/B (2,153 to 2,611) (41.7–50.6) (100 to 191) (1.9 to 3.7)
2015/16 1,825 34.5 876 16.6
A(H1N1)pmd09/B (1,701 to 1,952) (32.2 to 36.9) (782 to 973) (14.8 to 18.4)
2016/17 1,828 33.8 20 0.4
A(H3N2)/B (1,648 to 2,014) (30.4 to 37.2) (0 to 71) (0.0 to 1.3)
Aged 75 and older years
2011/12 3,122 75.5 3,098 74.9
A(H3N2)/B (2,737 to3,523) (66.2 to 85.1) (2,545 to 3,686) (61.5 to 89.1)
2012/13 6,103 144.9 1,232 29.2
A(H3N2)/B (5,281 to 6,964) (125.4 to 165.3) (838 to 1,672) (19.9 to 39.7)
2013/14a
NAa NAa NAa NAa
A(H1N1)pdm09
2014/15 18,680 427.0 3,626 82.9
A(H3N2)/B (17,657 to 19,722) (403.6 to 450.8) (3,105 to 4,173) (71.0 to 95.4)
2015/16 3,033 68.5 1,194 27.0
A(H1N1)pdm09/B (2,636 to 3,449) (59.6 to 77.9) (875 to 1,544) (19.8 to 34.9)
2016/17 9,628 215.4 433 9.7
A(H3N2)/B (8,878 to 10,399) (198.6 to 232.7) (175 to 759) (3.9 to 17.0)
CI: confidence interval; NA: not available.
aThe model could not attribute deaths for this period.
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Glasgow (HPS scheme). In Northern Ireland samples 
were sent to the Regional Virus Laboratory, Belfast.
Vaccination status
Cases and controls were defined as vaccinated if the 
date of vaccination that season was 14 or more days 
before onset of ILI. Cases and controls with less than 
14 days between vaccination and onset of illness were 
excluded, as their immune status was unclear. If the 
date of vaccination was missing it was assigned 15 
October, which was the median of all known vaccina-
tion dates. If the date of onset of symptoms was miss-
ing, then the individual was excluded. Respiratory 
samples with more than 7 days delay between onset 
of illness and sample collection were excluded, as the 
sensitivity of the PCR test decreases over longer inter-
vals between onset and sampling.
Statistical analysis
Average VE over the entire seven-season period 
(2010/11–2016/17) was estimated as 1-(OR) using mul-
tivariable logistic regression models with influenza 
A(H3N2), A(H1N1)pdm09 or influenza B PCR results as 
outcomes and seasonal vaccination status as the lin-
ear predictor. Age (coded into three age groups 65–74, 
75–84 and  85 years and older), sex, season, clinical 
risk group, surveillance scheme (RCGP, SMN, HPS, 
Public Health Wales, Northern Ireland) and date of 
sample collection (month) were investigated as poten-
tial confounding variables.
To investigate whether the VE changed in relation to 
time since vaccination, influenza VE was stratified by 
time since vaccination (<  3 months, ≥  3 months). To 
investigate whether the VE changed with age, an inter-
action term between vaccination and age (as a con-
tinuous variable) was included in the model. To test 
the significance of changes in VE with the time since 
vaccination, multivariable logistic regression was per-
formed with time between vaccination and onset of 
symptoms (days) included as a continuous variable. As 
testing for evidence of waning immunity was one of the 
study objectives, multiple testing adjustments were 
not made.
All statistical analyses were carried out in Stata version 
13 (StataCorp, College Station, Texas).
Results
Influenza vaccine uptake in those aged 65 years 
and older, influenza season 2016/17
During influenza season 2016/17, among 65–69-year-
olds in England, influenza vaccine uptake was 64% 
(55,818/87,566) compared with 74% (52,873/71,298) 
in 70–74 year olds and 80% (71,072/89,228) for those 
aged between 75–84 years or aged 85 years and older 
(28,143/35,097). The majority (99,215/124,325) of peo-
ple vaccinated in 2016/17 had received one or more 
doses of IIV in the previous 5 years, with most of those 
aged over 70 years having received all five doses of IIV 
that they were eligible for over the previous five sea-
sons (Table 1).
Influenza-associated mortality in those 
aged 65 years and older, influenza seasons 
2011/12–2016/17
During influenza seasons 2011/12–2016/17 in England, 
influenza-associated mortality estimates were higher 
in both the 65–74-year-olds and those aged 75 years 
and older during influenza A(H3N2) compared with 
A(H1N1)pdm09 dominated seasons (Table 2). Over five 
seasons with available data, average annual mortality 
rates for influenza A and B in those aged 75 years and 
older were 186.3 and 44.7 per 100,000 population vs 
22.5 and 5.0 for 65–74-year-olds, respectively.
Vaccine effectiveness in those aged 65 years and 
older, influenza seasons 2010/11–2016/17
A total of 3,679 swabs were taken in those over 65 years 
and older over influenza seasons 2010/11–2016/17, 
with 2,096 swabs used in the final analysis: of these 
1,702 were controls; 101 were flu B, 57 were A(H1N1)
pdm09, 215 were A(H3N2) and 21 A non-subtyped. The 
reasons samples were discarded are outlined in Figure 
1. The demographic and clinical details of the cases 
and controls remaining in the study stratified by swab 
result are given in  Table 3  including by scheme, sex, 
age, month, onset to swab, year and vaccination status.
Figure 1
Flowchart to show case and control ascertainment, United 




Swabbed before start of study (n=85)
Flu status unknown (n=23)
Vaccination status unknown (n=103)
Vaccinated less than 14 days before symptom onset (n=176)
Onset missing (n=262)
Swabbed before onset or more than 7 days after onset (n=934)
N=2,096





Inﬂuenza A unknown (n=21) 
Inﬂuenza B (n=101)
Inﬂuenza A(H1N1) pdm09 (n=57)
Inﬂuenza A(H3N2) (n=215)
5www.eurosurveillance.org
When estimating VE, key confounders were adjusted 
for in a multivariable logistic regression model, all of 
which (except age and sex) were associated with a pos-
itive swab (Table 3). Season and month were identified 
as confounders for the vaccine effects as the overall 
estimates changed by more than 5%.
The crude and adjusted VE (aVE) estimates in those 
aged 65 years and older by season are shown in Figure 
2, including what was the dominant circulating influ-
enza sub-type that season. The annual aVE point 
estimate against any laboratory-confirmed influenza 
infection in those aged 65 years and older ranged from 
-  2.7% (95% CI: -  88.8 to 44.2) in 2016/17 to 78.8% 
(95% CI: 18.8 to 94.5) in 2011/12. 
Over the seven-season period, for any influenza 
(A and B), the crude seasonal average VE in those aged 
Table 3
Details for influenza A and B in cases and control aged 65 years and older, test–negative influenza case–control study, 
United Kingdom, influenza seasons 2010/11–2016/17
Characteristics Controls Percent
Influenza type
B Percent A(H1N1)pdm09 Percent A(H3N2) Percent A (Unknown) Percent
Schemea
Northern Ireland 64 65.3 4 4.1 3 3.1 20 20.4 7 7.1
RCGP (England) 831 80.9 51 5.0 36 3.5 107 10.4 2 0.2
SMN (England) 122 89.1 3 2.2 3 2.2 9 6.6 0 0.0
Scotland 652 83.3 39 5.0 11 1.4 70 8.9 11 1.4
Wales 33 64.7 4 7.8 4 7.8 9 17.6 1 2.0
Sex
Female 1,040 81.6 53 4.2 30 2.4 137 10.8 14 1.1
Male 655 80.5 48 5.9 27 3.3 77 9.5 7 0.9
Missing 7 87.5 0 0.0 0 0.0 1 12.5 0 0.0
Age group
65–74 1,084 81 76 5.7 42 3.1 124 9.3 13 1.0
75–84 487 87.2 21 3.6 12 2.0 64 10.9 5 0.8
≥ 85 131 78 4 2.4 3 1.8 27 16.1 3 1.8
Montha
October 218 98.6 1 0.5 0 0.0 1 0.5 1 0.5
November 283 98.3 3 1.0 1 0.3 1 0.3 0 0.0
December 397 80.4 21 4.3 15 3.0 61 12.3 0 0.0
January 400 77.5 27 5.2 18 3.5 66 12.8 5 1.0
February 223 69.9 21 6.6 11 3.4 58 18.2 6 1.9
March 130 65.0 24 12.0 12 6.0 25 12.5 9 4.5
April 51 87.9 4 6.9 0 0.0 3 5.2 0 0.0
Onset of symptoms to swaba
0–1 days 165 77.1 7 3.3 7 3.3 33 15.4 2 0.9
2–4 days 766 78.1 55 5.6 31 3.2 116 11.8 13 1.3
5–7 days 771 85.6 39 4.3 19 2.1 66 7.3 6 0.7
Influenza seasona
2010/11 222 84.7 24 9.2 16 6.1 0 0.0 0 0.0
2011/12 232 91.7 2 0.8 0 0.0 19 7.5 0 0.0
2012/13 196 73.1 32 11.9 0 0.0 38 14.2 2 0.7
2013/14 144 92.9 0 0.0 0 0.0 3 1.9 8 5.2
2014/15 249 70.9 12 3.4 1 0.3 84 23.9 5 1.4
2015/16 346 84.6 19 4.6 39 9.5 4 1.0 1 0.2
2016/17 313 78.6 12 3.0 1 0.3 67 16.8 5 1.3
Vaccinationa
Unvaccinated 551 82.4 41 6.1 28 4.2 44 6.6 5 0.7
14–91 days before onset 666 87.7 13 1.7 11 1.4 66 8.7 3 0.4
> 92 days before onset 485 72.6 47 7.0 18 2.7 105 15.7 13 1.9
RCGP: Royal College of General Practitioners Research and Surveillance Centre; SMN: specialist regional microbiology laboratories.
a P value was < 0.001.
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65 years and older was - 12.0% (95% CI: -42.1 to 11.8), 
which increased to a seasonal average of 32.5% (95% 
CI: 11.6 to 48.5), when fully adjusted over the entire 
study period (Table 4). By sub-type aVE in all those 
aged 65 years and older for A(H3N2) was 5.6% (95% 
CI: - 39.2 to 35.9), compared with 60.8% (95% CI: 33.9 
to 76.7) and 50% (95% CI: 21.6 to 68.1) for A(H1N1)
pdm09 and B respectively. By age group, the aVE was 
54.2% (95% CI: 25.1 to 60.0) in 65–74-year-olds com-
pared with only -26.3% (95% CI: -149.3 to 36.0) for 
75–84-year-olds and -3.2% (95% CI: -237.8 to 68.5) 
in those aged 85 years and older. The vaccine dem-
onstrated significant effectiveness against A(H1N1)
pdm09 and B in 65–74-year-olds, but not in those aged 
75 years and older (Table 4).
We found that the aVE for all influenza types in those 
aged 65 years and older reduced by 6.1% for each year 
older (95% CI: -  10.5 to -  1.9: p  =  0.004). For A(H3N2) 
the aVE reduced by 6.6% (95% CI: -  12.8 to -  0.7: 
p  =  0.03); for A(H1N1)pdm09, by 1.9% (95% CI: -  10.4 
to 5.9: p = 0.64) and for influenza B, by 5.5% (95% CI: 
- 14.1 to 2.5: p = 0.19) for each year older.
For all laboratory-confirmed influenza cases the aVE 
by time since vaccination, within 3 months of symptom 
onset, was 44.7% (95% CI: 21.2 to 61.2) compared with 
14.5% (95% CI: - 18.2 to 38.2) for more than 3 months 
between onset and vaccination. For A(H3N2), the aVE 
was 13.6% (95% CI: - 41.4 to 47.2) if onset was within 
3 months of vaccination compared with -  7.1% (95% 
CI: -  69.7 to 32.5) for more than 3 months since vac-
cination. For A(H1N1)pdm09, aVE was 66.7% (95% CI: 
30.2 to 84.1) compared with 59.1% (95% CI: 23.2 to 
78.2) and finally for influenza B, aVE was 71.5% (95% 
CI: 43.0 to 85.8) compared to 19.1% (95% CI: - 40.2 to 
53.3).
Discussion
We found that despite achieving very high influenza 
vaccine uptake in those aged 65 years and older, the 
average annual age group-specific influenza-asso-
ciated mortality risk in England was highest in those 
aged 75 years and older over a six-season period and 
during seasons dominated by circulation of influenza 
A(H3N2). Over the seven seasons (2010/11–2016/17), 
the pooled aVE against all-laboratory confirmed influ-
enza diagnosed in primary care across the UK was mod-
erate in those 65 years and older. There was, however, 
Figure 2
Crude and adjusted vaccine effectiveness estimates in those aged 65 years or older, by influenza season and dominant 
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Inﬂuenza season and dominant viruses 
Blue dots represent annual adjusted vaccine effectiveness point estimates against any laboratory-confirmed influenza infection in those aged 
65 years or older. Black vertical lines are 95% confidence intervals.
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no evidence of statistically significant VE in those aged 
75 years and older nor specifically against A(H3N2).
We found evidence of high vaccine uptake, with 
increasing uptake with age in excess of 80% in those 
aged 75 years and older, which is comparable to other 
European countries [14]. England has one of the high-
est coverage figures in this target group and those 
aged 75 years and older had received multiple vaccina-
tions over prior seasons. Despite high vaccination cov-
erage over the study period, the influenza-associated 
mortality was high, particularly in those aged 75 years 
and older, with the average influenza-associated mor-
tality risk being seven times higher compared with that 
seen in 65–74-year-olds. Our findings are consistent 
with an earlier study by Hardelid et al. [5], who while 
investigating the period 1999–2010 in England, found 
that the season with the largest number of deaths 
associated with influenza was 1999/2000. This was a 
period of time before the introduction of the universal 
influenza vaccine programme aimed at those aged 65 
years and older when the dominant circulating sub-
type was influenza A(H3N2). We found that influenza-
associated mortality has generally been lower since 
that period, yet there remains statistically significant 
excess mortality in those aged 65 years and older, par-
ticularly in seasons dominated by intense circulation 
of influenza A(H3N2). Although influenza A is mainly 
responsible for influenza-associated mortality among 
those aged 65 years and older, influenza B also poses 
a risk; Influenza B associated deaths contributed a 
large proportion of seasonal mortality particularly 
in the 2011/12 and 2014/15 seasons. For example, in 
2014/15 WHO recommended that the annual influenza 
vaccine be composed of B/Massachusetts/2/2012-like 
virus of the B/Yamagata lineage, but the dominant cir-
culating strains were antigenically more closely related 
to B/Phuket/3073/2013, which is another influenza B/
Yamagata lineage virus. Reduced aVE against influenza 
B was observed in those aged 65 years and older that 
season, suggesting a mismatch [15]. This association 
between influenza burden and increasing age empha-
sise the importance of the ageing process on innate 
and adaptive immunity to influenza infection.
We demonstrate that over the 7 year study period, 
there was overall evidence of moderate aVE in those 
aged 65 years and older, though this obscures some 
important reductions by season, influenza subtype 
and age group. Immunosenescence is a key contribu-
tory factor with overall aVE decreasing with age. Age-
related decline in humoral immune response following 
vaccination is a well-recognised phenomenon [16,17]. 
Irrespective of vaccination status, reduced humoral 
responses may be caused or compounded by a reduc-
tion in T-cell responsiveness, which may also impair 
protection against more severe infection [18]. In addi-
tion to aVE decreasing with increasing age, we found 
that although the vaccine protects against influenza 
A(H1N1)pdm09 and influenza B, it did not against 
Table 4
Crude and adjusted vaccine effectiveness estimates for influenza by age group and subtype, test–negative case–control study, 
in those aged 65 years and older, United Kingdom, influenza seasons 2010/11–2016/17
Type/Subtype Age group





(95% CI)Unvacc Vacc Unvacc Vacc
A or B
All ≥ 65 years 118 276 551 1151 - 12.0 (- 42.1 to 11.8) 32.5 (11.6 to 48.5)
65–74 years 87 157 370 714 17.0 (- 10.0 to 37.4) 45.2 (25.1 to 60)
75–84 years 14 88 134 353 - 138.6 (- 333.9 to -31.2) - 26.3 (- 149.3 to 36.0)
≥ 85 years 6 31 47 84 - 189.1 (- 643.2 to - 12.4) - 3.2 (- 237.8 to 68.5)
A(H1)pdm09
All ≥ 65 years 33 38 551 1151 44.9 (11.2 to 65.8) 60.8 (33.9 to 76.7)
65–74 years 28 25 370 714 53.7 (19.5 to 73.4) 68.4 (41.7 to 82.9)
75–84 years 2 11 134 353 - 108.8 (- 854.3 to 54.3) - 40.8 (- 643.7 to 73.3)
≥ 85 years 3 2 47 84 NA NA
A(H3N2)
All ≥ 65 years 47 173 551 1151 - 76.2 (- 147.1 to - 25.7) 5.6 (- 39.2 to 35.9)
65–74 years 37 91 370 714 - 27.5 (- 90.6 to 14.8) 23.3 (- 20.9 to 51.4)
75–84 years 7 58 134 353 - 214.5 (- 606.4 to - 40.1) - 40.9 (- 264.2 to 45.5)
≥ 85 years 3 24 47 84 - 347.6 (- 1465.8 to - 28.0) - 91.0 (- 806.6 to 59.8)
B
All ≥ 65 years 41 60 551 1151 30.0 (- 5.6 to 53.5) 50.0 (21.6 to 68.1)
65–74 years 36 40 370 714 42.4 (8.1 to 63.9) 57.9 (29.8 to 74.7)
75–84 years 5 16 134 353 - 21.5 (- 238.1 to 56.4) 33.3 (- 110.9 to 78.9)
≥ 85 years 0 4 47 84 NA NA
CI: confidence interval; NA: Not available; Unvacc: unvaccinated; Vacc: vaccinated.
aAdjusted for age group, sex, season, month and surveillance scheme.
Numbers too small to estimate are indicated by NA.
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A(H3N2) [19,20]. This lower aVE against laboratory-
confirmed A(H3N2) infection in primary care in those 
aged 65 years and older was previously found for the 
2016/17 Northern hemisphere A(H3N2) dominated 
season—not only in the UK [6] but also elsewhere in 
Europe [21] and then subsequently in the 2017 winter 
season in Australia. All of these locations experienced 
circulation of influenza A(H3N2) 3C.2a sub-clades dur-
ing this period [22]. There seem to be several factors 
explaining these observations. Firstly, reduced VE for 
H3N2 over several years could have been caused by an 
antigenic mismatch between the circulating strain and 
vaccine virus, as was seen in 2014/15 [10]. Secondly, 
there could be amino acid differences between the egg-
adapted vaccine strain compared with the wild-type 
circulating strains leading to a mismatch in induced 
immunity, as was reported for A(H3N2) in recent sea-
sons [23-25]. Thirdly, we also demonstrate the poten-
tially important role of waning effectiveness within the 
season, a finding that has been highlighted previously, 
and which has a variable effect depending on the tim-
ing of the influenza epidemic, which is unpredictable 
between October and March [26]. Finally, we found that 
vaccinated individuals aged 65 years and older were 
more likely to have received multiple prior vaccinations, 
which is consistent with previous studies and indicates 
that a major predictor of being vaccinated is receiving 
vaccine the season before [27]. Taken together, these 
observations suggest that vaccine-induced immunity, 
particularly to H3N2, may need to be further optimised 
in those 65 years and older and suggests the neces-
sity for improved vaccine strain selection and vaccine 
formulation, an observation that has been recognised 
by WHO.
What potential interventions do we have to improve vac-
cine performance and potentially reduce the remaining 
disease burden in this age group? Improving protection 
through the induction of higher levels of antibody and/
or broader repertoires of antibody responses are ways 
of improving vaccine-induced immunity. Until recently, 
only normal-dose, non-adjuvanted influenza vaccines 
were licensed for use in those 65 years and older in 
the UK, but newer influenza vaccines are becoming 
increasingly available. MF59 adjuvanted vaccines pro-
vide a future alternative option—with effectiveness 
data from North America and Europe [28-30], suggest-
ing superiority compared with the current generation 
of influenza vaccines. These vaccines have recently 
been licensed in the UK. Higher antigen dose inacti-
vated vaccine, which is licensed in the United States 
for those aged 65 years and older and for which obser-
vational data provide encouraging results, provides an 
alternative option [31,32]. Cell grown and recombinant 
influenza vaccines are produced independently of eggs 
and may have higher antigen content, with the latter 
showing superiority in those aged 50 years and older of 
age during a mismatched season (2014/15) compared 
with existing egg-produced vaccines [33]. Quadrivalent 
influenza vaccines, that provide coverage against both 
the influenza B lineages, are also becoming more 
available, providing a solution to the dilemma of which 
influenza B strain to include in a trivalent vaccine, and 
provide an incremental improvement on the breadth of 
induced immunity. However, the long-term goal must be 
a universal (or near-universal) vaccine that generates 
a high level of durable and cross-protective immunity 
against both seasonal and ideally pandemic viruses. In 
the meantime, more research is needed to understand 
the effects of egg-induced mutations, antigen dose, 
and repeated vaccination on clinical protection.
The UK is also in the process of rolling out a universal 
childhood influenza vaccine programme, targeting chil-
dren 2-10 years of age, with the intention of providing 
both direct protection to vaccinated children but also, 
by reducing their risk of infection and thus transmis-
sion, provide indirect protection to vulnerable at-risk 
groups including those that are 65 years and older. 
Modelling work by Hodgson et al has demonstrated the 
projected impact of a paediatric programme on older 
age group and predicts that the direct and indirect ben-
efits of vaccinating children against influenza should 
be realised in future years once programme rollout is 
achieved [34]. Early impact studies conducted in com-
munities where schoolchildren have received influenza 
vaccine have provided encouraging results of the indi-
rect effects of vaccinating children of primary school-
age [35].
It is important to highlight that prompt use of influenza 
antivirals in vulnerable populations for treatment and 
prophylaxis purposes is also important to mitigate the 
impact of severe influenza; particularly during A(H3N2) 
dominated seasons,. These medicines are, however, 
currently underutilised in primary care in the UK [36].
One of the key advantages of the TNCC approach is 
that the design allows control for key biases e.g. the 
propensity to consult, but confounders still need to be 
adjusted for. Pooling vaccine effectiveness estimates 
over a number of seasons has allowed for the further 
exploration of influenza sub-type and age-specific 
effects. However, the available numbers of samples 
limit the precision of some of the stratified estimates 
e.g. by age group and the ability to assess waning by 
type/sub-type. Some of the sub-set analyses should 
thus be interpreted with caution. Other published 
work has suggested that the TNCC design should con-
trol for a possible confounding effect due to frailty in 
older subjects [37]. Nevertheless, caution should be 
taken to not over interpret the mortality-associated 
findings presented here, as we do not know the mor-
tality rates by vaccination status and thus what propor-
tion of deaths might be preventable by more effective 
influenza vaccines. Further effectiveness studies could 
start to address this limitation through investigating 
more severe end-points, such as the impact on hospital 
admissions. Although our study examined protection 
against laboratory-confirmed influenza infection in pri-
mary care, recent work has also found that influenza 
vaccine provided poor protection against influenza 
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A(H3N2) confirmed hospitalisation in those 65 years 
and older, particularly in those aged over 80 years [38]. 
Similar studies examining protection against influenza-
related mortality end-points are, however, urgently 
required and are planned through linkage of routine 
healthcare data [39].
Conclusion
Despite high vaccine uptake with non-adjuvanted, 
normal-dose inactivated vaccine in older people in 
the UK, influenza remains an important cause of influ-
enza-associated mortality, particularly due to influ-
enza A(H3N2) and in those aged 75 years and older. 
The forthcoming policy of administering adjuvanted 
vaccines to older people in the UK will provide the 
opportunity to improve the prevention and control of 
influenza in these older age groups, with guidance for 
their use particularly in those aged 65 years and older 
recently published [11]. Further studies are required 
to understand the performance of these vaccines in 
comparison to traditional influenza vaccines against a 
range of end-points.
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